(RTTNews) - Eli Lilly (LLY) and Hims & Hers Health (HIMS) have entered into an agreement to expand access to Lilly's FDA-approved obesity treatments through the Hims & Hers telehealth platform.

Lilly, Hims & Hers Partner To Expand Access To Weight-Loss Medicines; Stock Up 

(RTTNews) - Eli Lilly and Company (LLY), a global pharmaceutical company, announced plans to present new clinical and real-world research on retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) at the American College of Rheumatology (ACR) Convergence 2026, scheduled for No

Lilly To Present New Retatrutide, Taltz And Zepbound Data At ACR Convergence 2026 

Key PointsEli Lilly’s impressive run looks likely to continue over the next few years.

2 Growth Stocks to Buy in November Without Any Hesitation

Key PointsThe company reported 39% revenue growth last quarter and also raised its guidance for the full year.

Eli Lilly Stock: Is It Still a Buy at $1,400?

Key PointsEli Lilly’s GLP-1 portfolio drove another earnings beat in the third quarter.

Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy? 

Key PointsThere are new markets for GLP-1 drugs, particularly outside the U.S.

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company News